Retrieved from Jastreboff, A
Clinical studies Despite their thriving role in the treatment of obesity 214 , only seven studies investigated the effects of GLP-1RAs in eating disorders (Table 6), including some on their psychopathology in comorbid obesity 215,216,217 and others specifically in binge-eating disorder (BED) 217,218,219,220 , and we could not find any ongoing trial in this area
Michael Buontempo, a resident physician at Dartmouth-Hitchcock Medical Center, explains: Most hair shedding on GLP-1s looks like androgenetic alopecia unmasked by an episode of telogen effluvium driven by the magnitude of weight loss, rather than a direct drug toxicity. This means some people discover they have genetic hair loss when the telogen effluvium pulls away enough hair to reveal the underlying pattern
At the full 12mg maintenance dose, the majority experience some degree of nausea during the first few weeks, though this typically fades substantially by weeks 8-12 at that dose level
